Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070094 | 1.00 | RORC (0.55) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL16032347 | 1.00 | RORC (0.55) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL27688526 | 0.88 | RORC (0.49) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL4483556 | 0.88 | RORC (0.49) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL4483563 | 0.88 | RORC (0.49) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL4944424 | 0.88 | RORC (0.49) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL4483553 | 0.88 | RORC (0.49) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL16109014 | 0.88 | ENPP2 (0.51) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL14934468 | 0.88 | ENPP2 (0.51) | RORCPDE4BHDAC1HDAC2TACR1 | |
| SCHEMBL14610186 | 0.88 | ENPP2 (0.51) | RORCPDE4BHDAC1HDAC2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-1670476-A4 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| CN-1859914-A | Phenyl pyrrolidine ether tachykinin receptor antagonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1670476-A2 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005032464-A2 | PHENYL PYRROLIDINE ETHER TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | RORC 4254/4885PDE4B 2609/4885HDAC1 1996/4885 |
| US-20140275087-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | RORC 4254/4885PDE4B 2609/4885HDAC1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.